SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback